MRTX is a biotech company working on oncology drugs. They don't have a single product on the market and are currently in Phase II for two (?) different drugs.
They only have enough cash flow 'til the end of 2018, they lose a ton of money per share, yet their stock continues to climb upwards at low volume.
The past week, they rallied up from low $13/Share to low $15/Share with low volume and no news.
One or two months ago, they went from $4/Share to $14/Share on news of one of their drugs passing Phase I testing (rolls eyes).
Thoughts?
Submitted November 12, 2017 at 11:47PM by SubiWhale http://ift.tt/2AFpn1K
No comments:
Post a Comment